Institut für Klinische Pharmakologie
  1. Startseite LMU Klinikum
  2. Institut für Klinische Pharmakologie
  3. Joint Symposium Immunooncology 2026
News | 07/04/2026

Joint Symposium “Reaching new grounds in immunooncology” at LMU Klinikum München

Stephan Beissner
Prof. Sebastian Kobold at the joint Symposium "Reaching new grounds in immunooncology"

On 6 March 2026, the joint symposium of the Clinician-Scientist Programmes IOLIN: Local Therapies and Immunooncology and the international Graduate School i-Target 2.0 took place at the Klinikum of Ludwig-Maximilians-Universität München.

The symposium was held on the occasion of the appointment of Univ.-Prof. Dr. med. Sebastian Kobold as Director of the Institute for Clinical Pharmacology at LMU München and brought together leading international experts in immunooncology to discuss new developments and future perspectives in cancer immunotherapy.

Stephan Beissner
Group photo: From left to right: Dr. med. Thu Nguyen, Univ.-Prof. Dr. med. Sebastian Kobold, Dr. med. Simon Grassmann, Prof. Dr. med. Markus Lerch, Prof. Laurence Zitvogel, Prof. Dr. med. Julia Mayerle, Dr. Christian Klein and Kathrin Gabriel.

Following the welcome addresses by representatives of LMU and LMU Klinikum, the scientific programme featured distinguished speakers from internationally renowned institutions. Prof. Laurence Zitvogel (Gustave Roussy Cancer Center, Paris) presented innovative approaches on harnessing the microbiome in immunotherapies. Dr. Christian Klein (Biotech startup Zürich) discussed next-generation protein therapeutics in cancer immunotherapy, while Dr. Simon Grassmann (Memorial Sloan Kettering Cancer Center, New York) provided new insights into NK cell biology and its therapeutic implications.

Stephan Beissner
Audience: Full attendance during the keynote lecture of Univ.-Prof. Dr. med. Sebastian Kobold at the joint symposium in St. Vinzenz House, LMU Klinikum München.

In his keynote lecture, Prof. Sebastian Kobold presented current advances in engineering T cells for next-generation cancer therapeutics and outlined future directions of clinical pharmacology and immunooncology research at LMU.

Stephan Beissner
 Keynote lecture: Univ.-Prof. Dr. med. Sebastian Kobold presenting his keynote lecture on next-generation cancer immunotherapies at the joint symposium “Reaching new grounds in immunooncology”.

The symposium concluded with closing remarks by Prof. Kobold and a reception in the foyer of St. Vinzenz House, offering participants the opportunity for scientific exchange and networking.